12th Feb 2021 16:24
Syncona Ltd - London-based life sciences investor - Portfolio firm Gyroscope Therapeutics Ltd announces positive interim safety, protein expression and biomarker data from the open-label Phase I/II Focus clinical trial of its gene therapy GT005, for patients with geographic atrophy secondary to age-related macular degeneration.
Data showed that GT005 was well tolerated in patients.
"We are highly encouraged by the early data from Gyroscope's Phase I/II Focus trial, which suggests that the administration of GT005 leads to sustained expression of CFI and down-regulation of the complement system - a part of the inflammatory system which has been strongly linked as a cause of dry AMD," said Chris Hollowood, chief investment officer of Syncona Investment Management Ltd.
Current stock price: 257.50 pence
Year-to-date change: down 1.3%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Syncona